Metraipolis › archive › dc_f86b00ff1ec7
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights — Europe PMC PMID:41015967
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41015967
- DOI
- 10.1007/s00520-[numero omesso]-4
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T17:44:02.201Z
- SHA-256 of the archived text
5e995db504bfc0bb335138da49ba9a7854903baab821bc892afd0908904aca70- Stable URL of this page
https://metraipolis.com/documento/dc_f86b00ff1ec7
How to cite
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights — Europe PMC PMID:41015967 — Europe PMC (en), https://europepmc.org/article/MED/41015967 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f86b00ff1ec7 (Metraipolis archive dc_f86b00ff1ec7, sha256 5e995db504bfc0bb335138da49ba9a7854903baab821bc892afd0908904aca70)
BibTeX
@misc{dcf86b00ff1ec7,
title = {Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights — Europe PMC PMID:41015967},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41015967},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f86b00ff1ec7; sha256 5e995db504bfc0bb335138da49ba9a7854903baab821bc892afd0908904aca70},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41015967. Agents can read the archived copy with the MCP tool read_document.